# MIER1

## Overview
The MIER1 gene encodes the Mesoderm Induction Early Response protein 1, a transcriptional regulator involved in chromatin remodeling and transcriptional repression. This protein is characterized by its ELM2 and SANT domains, which facilitate interactions with histone deacetylase 1 (HDAC1) and other proteins, playing a crucial role in modulating chromatin structure and gene expression (Ding2003Human). MIER1 is known for its histone chaperone activity and its involvement in a complex that includes HDAC1, BAHD1, and C1QBP, which is associated with repressed chromatin regions (Wang2022An). The protein's function and localization are influenced by alternative splicing and post-translational modifications, resulting in different isoforms with distinct roles in cellular processes such as differentiation and development (Paterno2002Genomic; Ding2003Human). MIER1's clinical significance is highlighted by its role in breast cancer progression and liver regeneration, where alterations in its expression and localization can impact disease outcomes (McCarthy2008Changes; Chen2023Acute).

## Structure
The MIER1 protein is characterized by several conserved domains that contribute to its function as a transcriptional regulator. It contains an ELM2 domain, which is crucial for recruiting histone deacetylase 1 (HDAC1) and mediating transcriptional repression (Ding2003Human). The ELM2 domain is located between amino acids 179 to 283 and is essential for HDAC1 binding (Ding2003Human). Additionally, the protein includes a SANT domain, which is involved in DNA binding and protein-protein interactions, particularly with the Sp1 protein, interfering with Sp1's ability to recognize GC boxes (Ding2004The).

The MIER1 protein undergoes alternative splicing, resulting in multiple isoforms with distinct N- and C-terminal sequences. The two major isoforms, hMI-ER1α and hMI-ER1β, differ in their C-terminal domains, with the α isoform containing a motif for nuclear hormone receptor interaction and the β isoform containing a nuclear localization signal (Paterno2002Genomic; Ding2003Human). These isoforms also exhibit different subcellular localizations, with hMI-ER1β being nuclear and hMI-ER1α remaining cytoplasmic (Paterno2002Genomic; Ding2003Human). The protein's structure is further influenced by post-translational modifications, such as phosphorylation, which may affect its regulatory roles.

## Function
The MIER1 gene encodes the Mesoderm Induction Early Response protein 1, which functions as a transcriptional regulator involved in chromatin remodeling and transcriptional repression. MIER1 achieves this by recruiting histone deacetylase 1 (HDAC1) to its conserved ELM2 domain, leading to the removal of acetyl groups from lysine residues in histone tails, resulting in chromatin compaction and transcriptional repression (Wang2022An; Ding2003Human). This recruitment is crucial for the gene's role in modulating chromatin structure and gene expression in human cells (Ding2003Human).

MIER1 is part of a larger complex that includes HDAC1, BAHD1, and C1QBP, which co-purifies with nucleosomes bearing H3K27me2/3 marks. This suggests that MIER1 acts downstream of the PRC2 complex to expand repressed chromatin regions and deposit histone octamers onto nucleosome-depleted DNA regions (Wang2022An). The protein also exhibits histone chaperone activity, binding to H2A:H2B dimers and complete histone octamers, which is unique among known HDAC1/2 complexes (Wang2022An).

In terms of cellular localization, the MIER1 protein is active in the nucleus, where it interacts with chromatin and transcription factors to regulate gene expression, impacting processes such as differentiation and development (Paterno2002Genomic).

## Clinical Significance
Alterations in the expression and localization of the MIER1 gene have been implicated in breast cancer progression. MIER1 interacts with estrogen receptor alpha (ERα) and functions as a transcriptional repressor, inhibiting estrogen-stimulated growth in breast carcinoma cells. A notable shift in MIER1's subcellular localization from the nucleus to the cytoplasm is observed during breast cancer progression, which is associated with a reduction in its tumor-suppressing activity (McCarthy2008Changes; Li2013Nuclear). This shift in localization is influenced by factors such as insulin and insulin-like growth factor (IGF-1), which reduce MIER1's nuclear presence, potentially attenuating its transcriptional repressor functions (Li2015Insulin).

In liver regeneration, MIER1 acts as a negative regulator by repressing cell cycle gene expression through chromatin remodeling. Depletion of MIER1 leads to increased expression of cell cycle-relevant genes, suggesting its role in controlling liver cell proliferation. This regulatory function highlights MIER1's importance in liver health and disease, with potential implications for liver regeneration processes (Chen2023Acute). Understanding the mechanisms controlling MIER1's expression and localization could provide insights into its role in cancer and other diseases.

## Interactions
MIER1 interacts with several proteins and forms part of a histone deacetylase complex. It recruits histone deacetylase 1 (HDAC1) through its conserved ELM2-SANT domain, which is crucial for its function as a transcriptional repressor (Ding2003Human). MIER1 also interacts with HDAC2, and this interaction is necessary for its nuclear localization in breast cancer cells (Li2013Nuclear). 

The MIER1 protein is involved in a larger complex that includes HDAC1, BAHD1, and C1QBP. This complex specifically recruits nucleosomes marked with H3K27me2/3, indicating a role in chromatin remodeling and gene repression (Wang2022An). The BAH domain of BAHD1 interacts with the MIER1:HDAC1 complex, facilitating the recruitment of C1QBP, which co-purifies with the complex (Wang2022An). 

MIER1 also exhibits histone chaperone activity, binding to H2A:H2B dimers and complete histone octamers. This interaction is mediated by the amino-terminal region of MIER1 and is essential for its role in chromatin dynamics (Wang2022An). The protein's interaction with histones suggests its involvement in depositing or removing histones from chromatin (Wang2022An).


## References


[1. (Ding2004The) Zhihu Ding, Laura L. Gillespie, F. Corinne Mercer, and Gary D. Paterno. The sant domain of human mi-er1 interacts with sp1 to interfere with gc box recognition and repress transcription from its own promoter. Journal of Biological Chemistry, 279(27):28009–28016, July 2004. URL: http://dx.doi.org/10.1074/jbc.m403793200, doi:10.1074/jbc.m403793200. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m403793200)

[2. (Ding2003Human) Zhihu Ding, Laura L. Gillespie, and Gary D. Paterno. Human mi-er1 alpha and beta function as transcriptional repressors by recruitment of histone deacetylase 1 to their conserved elm2 domain. Molecular and Cellular Biology, 23(1):250–258, January 2003. URL: http://dx.doi.org/10.1128/mcb.23.1.250-258.2003, doi:10.1128/mcb.23.1.250-258.2003. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.23.1.250-258.2003)

[3. (Li2015Insulin) Shengnan Li, Gary D. Paterno, and Laura L. Gillespie. Insulin and igf-1, but not 17β-estradiol, alter the subcellular localization of mier1α in mcf7 breast carcinoma cells. BMC Research Notes, August 2015. URL: http://dx.doi.org/10.1186/s13104-015-1336-0, doi:10.1186/s13104-015-1336-0. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13104-015-1336-0)

[4. (Li2013Nuclear) Shengnan Li, Gary D. Paterno, and Laura L. Gillespie. Nuclear localization of the transcriptional regulator mier1α requires interaction with hdac1/2 in breast cancer cells. PLoS ONE, 8(12):e84046, December 2013. URL: http://dx.doi.org/10.1371/journal.pone.0084046, doi:10.1371/journal.pone.0084046. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0084046)

[5. (McCarthy2008Changes) P L McCarthy, F C Mercer, M W J Savicky, B A Carter, G D Paterno, and L L Gillespie. Changes in subcellular localisation of mi-er1α, a novel oestrogen receptor-α interacting protein, is associated with breast cancer progression. British Journal of Cancer, 99(4):639–646, July 2008. URL: http://dx.doi.org/10.1038/sj.bjc.6604518, doi:10.1038/sj.bjc.6604518. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.bjc.6604518)

6. (Wang2022An) An unexpected histone chaperone function for the MIER1 histone deacetylase complex. This article has 1 citations.

[7. (Paterno2002Genomic) Gary D. Paterno, Zhihu Ding, Yuan-Y. Lew, Gord W. Nash, F.Corinne Mercer, and Laura L. Gillespie. Genomic organization of the human mi-er1 gene and characterization of alternatively spliced isoforms: regulated use of a facultative intron determines subcellular localization. Gene, 295(1):79–88, July 2002. URL: http://dx.doi.org/10.1016/s0378-1119(02)00823-5, doi:10.1016/s0378-1119(02)00823-5. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0378-1119(02)00823-5)

[8. (Chen2023Acute) Yanhao Chen, Lanlan Chen, Xiaoshan Wu, Yongxu Zhao, Yuchen Wang, Dacheng Jiang, Xiaojian Liu, Tingting Zhou, Shuang Li, Yuda Wei, Yan Liu, Cheng Hu, Ben Zhou, Jun Qin, Hao Ying, and Qiurong Ding. Acute liver steatosis translationally controls the epigenetic regulator mier1 to promote liver regeneration in a study with male mice. Nature Communications, March 2023. URL: http://dx.doi.org/10.1038/s41467-023-37247-9, doi:10.1038/s41467-023-37247-9. This article has 12 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-37247-9)